News | January 18, 2024
NATCO invests US$ 2 million in Cellogen Therapeutics
Both these innovations are aimed at reducing the risk of relapse post CAR T cell therapy
Both these innovations are aimed at reducing the risk of relapse post CAR T cell therapy
The primary goal of this joint venture is to develop and commercialise novel cell therapy products for major unmet medical needs in the United States, Japan, and EU regions
This fresh infusion of capital will enable ImmunoACT to fast track the additional supply of the lead candidate HCAR-19
Lonza launches the TheraPEAK T-VIVO Cell Culture Medium with a novel chemically defined formulation developed to optimize and streamline CAR T-cell manufacturing
First disclosure from PILOT study of Breyanzi in second-line large B-cell lymphoma underscores important role of cell therapy earlier in treatment paradigm
Targeted action improves quality of healing of tendon and suspensory ligament injuries in horses
This is the first CAR T cell therapy application filed for the second-line treatment of R/R LBCL in Japan
Application based on the pivotal Phase 3 TRANSFORM study in which Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years
It is the first CAR T Therapy approved for the treatment of multiple myeloma in Japan
This next-generation CAR T construct was designed to improve the tolerability profile of conventional CD19 CAR Ts and developed in the laboratory of James N. Kochenderfer, M.D., at the National Cancer Institute, part of the NIH, the same laboratory that discovered axicabtagene ciloleucel
Subscribe To Our Newsletter & Stay Updated
